Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Prevention of Docetaxel (Doc)-Induced Neutropenia (DIN) with Single Agent Plinabulin (Plin) Versus (vs) Control (No-Treatment or Placebo) in Non-Small Cell Lung Cancer (NSCLC) in Two Randomized Trials

Douglas W. Blayney, Stephan Ogenstad, Gabrielle Legaspi, Stephen Duprez, Lan Huang, Ramon W. Mohanlal

Blood (2022) 140 (Supplement 1): 2610–2611.

https://doi.org/10.1182/blood-2022-166861

Published: 2022

Journal Articles

A Bioinformatic Approach to the Clinical Evaluation of Linear Commitment Versus Cloud (Continuum of Low Primed UnDifferentiated) Models for Hematopoiesis Using Plinabulin Clinical Trial Data

Ramon W. Mohanlal, June Lu, Lan Huang, Lorna Honour, Douglas W. Blayney

Blood (2022) 140 (Supplement 1): 11165–11166.

https://doi.org/10.1182/blood-2022-167277

Published: 2022

Journal Articles

Plinabulin Rapidly (within 24 Hours) Reverses Myelosuppression Induced By Chemotherapy

Douglas W. Blayney, Mengru Chang, Lan Huang, Ramon Mohanlal

Blood (2021) 138 (Supplement 1): 2056.

https://doi.org/10.1182/blood-2021-150920

Published: 2021

Journal Articles

Protective-2 (BPI-2358-106): A Confirmatory Trial to Demonstrate Superiority of the Plinabulin+Pegfilgrastim (Plin/Peg) Combination Versus Standard of Care Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia (CIN) in Breast Cancer (BC) Patients (pts)

Douglas W. Blayney, MD, Ramon Mohanlal, PhD MD, Lan Huang, PhD

Blood (2020) 136 (Supplement 1): 16.

https://doi.org/10.1182/blood-2020-141110

Published: 2020

Journal Articles

A Randomized Phase 3 Clinical Trial of the Combination of Plinabulin (plin) + Pegfilgrastim (peg) Versus (vs) Peg Alone for Tac (docetaxel, doxorubicin, cyclophosphamide) Induced Neutropenia (cin)

Douglas W. Blayney, MD, Lan Huang, PhD, Ramon Mohanlal, PhD MD

Blood (2019) 134 (Supplement_1): 3590.

https://doi.org/10.1182/blood-2019-127310

Published: 2019

Journal Articles

Clinical Evidence Against the Continuum of Low-Primed Uncommitted Hematopoietic and Progenitor Cells (CLOUD-HSPC) Concept for Hematopoiesis

Ramon Mohanlal, PhD MD, Douglas W. Blayney, MD, Lan Huang, PhD

Blood (2019) 134 (Supplement_1): 4860.

https://doi.org/10.1182/blood-2019-128563

Published: 2019

Journal Articles

Clinical Evidence of Granulocyte-Monocyte Progenitor (GMP) Stem Cell Involvement in Plinabulin's Mechanism of Action (MoA) for the Prevention of Docetaxel (Doc) Chemotherapy (Chemo)-Induced Neutropenia (CIN)

Douglas W. Blayney, MD, Lan Huang, PhD, Ramon Mohanlal, PhD MD

Blood (2019) 134 (Supplement_1): 4861.

https://doi.org/10.1182/blood-2019-127227

Published: 2019

Journal Articles

Plinabulin, a Novel Small Molecule in Development for Chemotherapy-Induced-Neutropenia (CIN) Prevention, Mobilizes CD34+ Cells through a Mechanism of Action (MoA) Different from G-CSF and from CXCR4 Inhibition

Douglas W. Blayney, MD, Ene Ette, PhD, Stephan Ogenstad, PhD, Yuankai Shi, MD PhD, Lihua Du, Kenneth Lloyd, PhD, Lan Huang, PhD, Ramon Mohanlal, PhD MD

Blood (2018) 132 (Supplement 1): 2068.

https://doi.org/10.1182/blood-2018-99-113569

Published: 2018

Journal Articles

Plinabulin, a Novel Small Molecule That Ameliorates Chemotherapy-Induced Neutropenia, Is Administered on the Same Day of Chemotherapy and Has Anticancer Efficacy

Douglas W Blayney, MD, Lyudmila Bazhenova, MD, G. Kenneth Lloyd, PhD, Lan Huang, PhD, Ramon Mohanlal, MD PhD

Blood (2016) 128 (22): 2508.

https://doi.org/10.1182/blood.V128.22.2508.2508

Published: 2016

Journal Articles

Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database

Ann S. LaCasce, Jonathan L. Vandergrift, Maria A. Rodriguez, Gregory A. Abel, Allison L. Crosby, Myron S. Czuczman, Auayporn P. Nademanee, Douglas W. Blayney, Leo I. Gordon, Michael Millenson, Ann Vanderplas, Eva M. Lepisto, Andrew D. Zelenetz, Joyce Niland, Jonathan W. Friedberg

Blood (2012) 119 (9): 2093–2099.

https://doi.org/10.1182/blood-2011-07-369629

Published: 2012

Journal Articles

Variations in Surveillance Imaging for Patients with Treated Diffuse Large B-Cell Lymphoma in the National Comprehensive Cancer Network (NCCN) Lymphoma Database.

Gregory A. Abel, MD, MPH, Ann Vanderplas, MS, Jonathan W. Friedberg, MD, Joyce Niland, PhD, Maria A. Rodriguez, MD, Myron S Czuczman, MD, Michael Millenson, MD, Allison L. Crosby, Leo I. Gordon, MD, Douglas W. Blayney, MD, Andrew D. Zelenetz, MD, PhD, Ann S. LaCasce, MD

Blood (2009) 114 (22): 1387.

https://doi.org/10.1182/blood.V114.22.1387.1387

Published: 2009

Journal Articles

R-CHOP, Followed by High Dose Therapy and Autologous Stem Cell Rescue (HDT/ASCR), and R-Hypercvad Have Equivalent Progression-Free Survival and Are Superior to R-CHOP Alone in Younger Patients with Mantle Cell Lymphoma: a Comparative Effectiveness Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma Outcomes Database Project.

Ann LaCasce, MD, Jonathan L. Vandergrift, MS, Maria A. Rodriguez, MD, Allison L. Crosby, MS, Eva M. Lepisto, MSc, MA, Myron S. Czuczman, MD, Auayporn P. Nademanee, MD, Douglas W. Blayney, MD, Leo I. Gordon, MD, Michael Millenson, MD, Ann Vanderplas, Gregory A. Abel, MD, MPH, Andrew D. Zelenetz, MD, PhD, Jonathan W. Friedberg, MD

Blood (2009) 114 (22): 403.

https://doi.org/10.1182/blood.V114.22.403.403

Published: 2009

Journal Articles

Implementation of Computerized Provider Order Entry (CPOE) Does Not Impact Provider Work Time in An Inpatient Malignant Hematology Service

David A Hanauer, MD, MS, Sung W Choi, MD, Robert W Beasley, Ronald B Hirschl, MD, Douglas W Blayney, MD

Blood (2008) 112 (11): 4704.

https://doi.org/10.1182/blood.V112.11.4704.4704

Published: 2008

Journal Articles

Development of the Anemia Impact Measure (AIM): A Disease-Specific Patient Reported Outcome (PRO) Instrument to Measure Anemia Symptoms and Their Impact on Functioning in Cancer Patients Receiving Chemotherapy

Leah Kleinman, DrPH, Katy Benjamin, PhD, Hema Viswanathan, PhD, Maria Stoeckl Mattera, MPH, Linda D. Bosserman, MD, FACP, Douglas W. Blayney, MD, Dennis Revicki, PhD

Blood (2008) 112 (11): 668.

https://doi.org/10.1182/blood.V112.11.668.668

Published: 2008

Journal Articles

Eighty-Five Cases of Lymphoma in a Solid Organ Transplant (SOT) Population: Risk, Treatment, and Histologic Subtype.

Jason S. Knight, MD, PhD, Alexander Tsodikov, Ph.D., Diane M. Cibrik, M.D., M.S., Charles W. Ross, M.D., Mark S. Kaminski, M.D., Douglas W. Blayney, M.D.

Blood (2007) 110 (11): 1367.

https://doi.org/10.1182/blood.V110.11.1367.1367

Published: 2007

Journal Articles

Efficacy of Darbepoetin Alfa in the Treatment of Chemotherapy-Induced Anemia in Non-Hodgkin’s Lymphoma.

Stephanie A. Gregory, MD, Douglas W. Blayney, MD, Saroj Vadhan-Raj, MD, Dianne K. Tomita, MPH, Greg Rossi, PhD, Barry Mirtsching, MD

Blood (2004) 104 (11): 3296.

https://doi.org/10.1182/blood.V104.11.3296.3296

Published: 2004

NARROW

Prevention of Docetaxel (Doc)-Induced Neutropenia (DIN) with Single Agent Plinabulin (Plin) Versus (vs) Control (No-Treatment or Placebo) in Non-Small Cell Lung Cancer (NSCLC) in Two Randomized Trials

A Bioinformatic Approach to the Clinical Evaluation of Linear Commitment Versus Cloud (Continuum of Low Primed UnDifferentiated) Models for Hematopoiesis Using Plinabulin Clinical Trial Data

Plinabulin Rapidly (within 24 Hours) Reverses Myelosuppression Induced By Chemotherapy

Protective-2 (BPI-2358-106): A Confirmatory Trial to Demonstrate Superiority of the Plinabulin+Pegfilgrastim (Plin/Peg) Combination Versus Standard of Care Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia (CIN) in Breast Cancer (BC) Patients (pts)

A Randomized Phase 3 Clinical Trial of the Combination of Plinabulin (plin) + Pegfilgrastim (peg) Versus (vs) Peg Alone for Tac (docetaxel, doxorubicin, cyclophosphamide) Induced Neutropenia (cin)

Clinical Evidence Against the Continuum of Low-Primed Uncommitted Hematopoietic and Progenitor Cells (CLOUD-HSPC) Concept for Hematopoiesis

Clinical Evidence of Granulocyte-Monocyte Progenitor (GMP) Stem Cell Involvement in Plinabulin's Mechanism of Action (MoA) for the Prevention of Docetaxel (Doc) Chemotherapy (Chemo)-Induced Neutropenia (CIN)

Plinabulin, a Novel Small Molecule in Development for Chemotherapy-Induced-Neutropenia (CIN) Prevention, Mobilizes CD34+ Cells through a Mechanism of Action (MoA) Different from G-CSF and from CXCR4 Inhibition

Plinabulin, a Novel Small Molecule That Ameliorates Chemotherapy-Induced Neutropenia, Is Administered on the Same Day of Chemotherapy and Has Anticancer Efficacy

Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database

Variations in Surveillance Imaging for Patients with Treated Diffuse Large B-Cell Lymphoma in the National Comprehensive Cancer Network (NCCN) Lymphoma Database.

Implementation of Computerized Provider Order Entry (CPOE) Does Not Impact Provider Work Time in An Inpatient Malignant Hematology Service

Development of the Anemia Impact Measure (AIM): A Disease-Specific Patient Reported Outcome (PRO) Instrument to Measure Anemia Symptoms and Their Impact on Functioning in Cancer Patients Receiving Chemotherapy

Eighty-Five Cases of Lymphoma in a Solid Organ Transplant (SOT) Population: Risk, Treatment, and Histologic Subtype.

Efficacy of Darbepoetin Alfa in the Treatment of Chemotherapy-Induced Anemia in Non-Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only